THE COST-EFFECTIVENESS OF RISPERIDONE LONG-ACTING INJECTION IN SCHIZOPHRENIA TREATMENT: A SYSTEMATIC REVIEW

被引：0
|
作者：
Li, H. [1 ]
Ren, J. [1 ]
Yu, X. [2 ]
机构：
[1] China Pharmaceut Univ, Nanjing, Jiangsu, Peoples R China
[2] Xian Janssen Pharmaceut Ltd, Beijing, Peoples R China
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A670 / A670
页数：1
相关论文
共 50 条
  • [1] The cost-effectiveness of risperidone long-acting injection in the treatment of schizophrenia
    Chue, Pierre
    Chue, James
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2012, 12 (03) : 259 - 269
  • [2] COST-EFFECTIVENESS ANALYSIS OF OLANZAPINE LONG-ACTING INJECTION COMPARED WITH RISPERIDONE LONG-ACTING INJECTION IN THE TREATMENT OF SCHIZOPHRENIA IN NORWAY
    Carroll, S. M.
    Jemiai, N.
    Suter, B.
    O'Donohoe, P.
    Skjoldborg, U.
    Moller, J.
    Kleivenes, O. K.
    Novick, D.
    VALUE IN HEALTH, 2009, 12 (07) : A358 - A358
  • [3] Cost-effectiveness evaluation of long-acting risperidone injection
    Edwards, N
    Rupnow, M
    Pashos, CL
    Botteman, MF
    Locklear, J
    Diamond, R
    VALUE IN HEALTH, 2004, 7 (03) : 270 - 270
  • [4] Cost-effectiveness model of long-acting risperidone in schizophrenia in the US
    Natalie C. Edwards
    Marcia F. T. Rupnow
    Chris L. Pashos
    Marc F. Botteman
    Ronald J. Diamond
    PharmacoEconomics, 2005, 23 : 299 - 314
  • [5] Cost and Cost-Effectiveness in a Randomized Trial of Long-Acting Risperidone for Schizophrenia
    Barnett, Paul G.
    Scott, Jennifer Y.
    Krystal, John H.
    Rosenheck, Robert A.
    JOURNAL OF CLINICAL PSYCHIATRY, 2012, 73 (05) : 696 - 702
  • [6] Cost-effectiveness model of long-acting risperidone in schizophrenia in the US
    Edwards, NC
    Rupnow, MFT
    Pashos, CL
    Botteman, MF
    Diamond, RJ
    PHARMACOECONOMICS, 2005, 23 (03) : 299 - 314
  • [7] COST-EFFECTIVENESS OF LONG-ACTING OLANZAPINE VERSUS LONG-ACTING RISPERIDONE IN PATIENTS WITH SCHIZOPHRENIA IN SPAIN
    Dilla, T.
    O'Donohoe, P.
    Moeller, J.
    Alvarez, M.
    Sacristan, J.
    San, L.
    Happich, M.
    Tockhorn, A.
    VALUE IN HEALTH, 2011, 14 (07) : A292 - A292
  • [8] Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain - a cost-effectiveness comparison
    Dilla, Tatiana
    Moeller, Joergen
    O'Donohoe, Paul
    Alvarez, Maria
    Sacristan, Jose A.
    Happich, Michael
    Tockhorn, Antje
    BMC PSYCHIATRY, 2014, 14
  • [9] Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain – a cost-effectiveness comparison
    Tatiana Dilla
    Jörgen Möller
    Paul O’Donohoe
    María Álvarez
    José A Sacristán
    Michael Happich
    Antje Tockhorn
    BMC Psychiatry, 14
  • [10] Cost and Cost-Effectiveness in a Randomized Trial of Long-Acting Risperidone for Schizophrenia Reply
    Barnett, Paul G.
    Rosenheck, Robert A.
    JOURNAL OF CLINICAL PSYCHIATRY, 2012, 73 (10) : 1358 - 1359
12345